Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study [Correction]

https://doi.org/10.1186/s12885-024-12225-6. Following publication of the original article [1], the authors reported an error in the funding section of their article. The correct funding statement is: The present study is an investigator-driven trial, carried out by participating clinicians, who have the intellectual ownership of the results. The study is sponsored by Gruppo Oncologico del Nord Ovest, Cooperative Group having its headquarters at Via G. Mameli, 3–16,122 Genoa (ITALY) and funded by GONO Foundation. Part of the funding is also provided by Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, through institutional funds and a nonconditional support of Fondazione Anna Villa e Felice Rusconi Onlus. This project is also in collaboration with Intesa Sanpaolo S.p.A. No funds can be provided to ethical committees and single participating centers. The study will be conducted according to the current regulations.